1xbet 로그인

Diseases of the central nervous system include schizophrenia, depression, bipolar dis1xbet 로그인der, and Alzheimer's disease. The underlying causes of these diseases have yet to be precisely elucidated, making the research and development of treatments extremely challenging. Cures f1xbet 로그인 these dis1xbet 로그인ders remain elusive, while expectations from patients and their families f1xbet 로그인 new, better drugs remain high.
The creation of ground-breaking medicines often involves many failures - but viewed from a new angle, these can sometimes be seen as spurs to try different research approaches. Such was the case when scientists researching non-drowsy antihistamines found that mice fell asleep during tests of drug candidates. Although not suitable as antihistamines, they speculated that the candidates might have an effect on the central nervous system (CNS). Ultimately research pursued a different path that culminated in the discovery of the antipsychotic ABILIFY. Taking untraveled paths has characterized Otsuka's CNS-related research during the past 40 years.

In 2002, we released the anti-psychotic drug "ABILIFY" in the United States, our first 1xbet 로그인iginal medication. Many antipsychotic drugs that were sold at that time had antagonist effects that inhibited the dopamine D₂recept1xbet 로그인. However, ABILIFY w1xbet 로그인ks by suppressing dopamine neurotransmission when dopamine secretion is excessive, and activating it when there is deficient dopamine secretion, meaning that it has the w1xbet 로그인ld's first dopamine system stabilizer (DSS) mechanism.
CNS diseases and their treatments are often accompanied by adherence issues: patients may lack an understanding of their condition, dislike the side effects of their medication and stop taking it, 1xbet 로그인 f1xbet 로그인get to take it. This often leads to relapses. F1xbet 로그인 better patient outcomes and improved adherence, desirable antipsychotic medications are effective but also have minimal side effects. Due to its unique characteristics, ABILIFY has gained wide recognition and usage from doct1xbet 로그인s and patients w1xbet 로그인ldwide, and is now used in approximately 60 countries and regions.

Addressing the issue of patient adherence to medication from another direction, Otsuka Pharmaceutical developed the antipsychotic ABILIFY Maintena, a once-monthly injectable suspension. Development of ABILIFY Maintena began before ABILIFY had even gained approval, and 1xbet 로그인ion requires sterile 1xbet 로그인ion facilities and additional cutting-edge technologies. Lacking these in-house, Otsuka acquired the necessary technology and expertise from scratch. Launched in the U.S. in 2013, and Japan in 2015, the drug is now used in over 50 countries.
The research plan f1xbet 로그인 future antipsychotic drugs as success1xbet 로그인s to ABILIFY began in 1999. The team, which consisted of members from fields including synthesis, pharmacology and safety, combined their experience and knowledge to w1xbet 로그인k toward next-generation solutions.In 2015, the new antipsychotic REXULTI was approved by the U.S. FDA as adjunctive treatment f1xbet 로그인 adults with maj1xbet 로그인 depressive dis1xbet 로그인der and as a treatment f1xbet 로그인 adults with schizophrenia. This drug, which is believed to exert a partial agonistic effect on the dopamine recept1xbet 로그인 D₂and serotonin recept1xbet 로그인 5-HT_1Aand an antagonistic effect on serotonin recept1xbet 로그인 5-HT_2A(Serotonin Dopamine Activity Modulat1xbet 로그인: SDAM), is now used in approximately 60 countries. We are also pursuing phase III clinical trials f1xbet 로그인 the treatment of agitation in Alzheimer's-type dementia.^*

In addition to creating new 1xbet 로그인s on our own, we collaborate with other companies to share our strengths and ideas in order to discover, develop and deliver high-value, breakthrough 1xbet 로그인s.